Clinical trials
Withdrawn Depressive Disorder trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 20 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Mental Health (NIMH) | 3 |
| Butler Hospital | 1 |
| Centre for Addiction and Mental Health | 1 |
| Cybin Therapeutics Inc. | 1 |
| GlaxoSmithKline | 1 |
| Harvard School of Public Health (HSPH) | 1 |
| Jay Fournier | 1 |
| Kaiser Permanente | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| Massachusetts General Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Depressive Disorder | 20 |
| Major Depressive Disorder | 9 |
| Anxiety Disorders | 5 |
| Mental Disorders | 3 |
| Depressive Disorder, Treatment-Resistant | 2 |
| Mood Disorders | 2 |
| Agnosia | 1 |
| Bipolar Disorder | 1 |
| Chronic Pain | 1 |
| Depression, Postpartum | 1 |
Trials
Showing 76 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.